A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: A cohort study of 1249 patients

Digestive Diseases and Sciences

Volumn 51, Issue 3, 2006, Pages 603-609

  Ikeda, Kenji ^a   Arase, Yasuji ^b   Kobayashi, Masahiro ^b   Saitoh, Satoshi ^b   Someya, Takashi ^b   Hosaka, Tetsuya ^b   Sezaki, Hitomi ^b   Akuta, Norio ^b   Suzuki, Yoshiyuki ^b   Suzuki, Fumitaka ^b   Kumada, Hiromitsu ^b  

^a TORANOMON HOSPITAL   (Japan)

^b NONE

Author keywords

Cancer prevention; Chronic hepatitis; Glycyrrhizin; Hepatitis C virus; Hepatocellular carcinogenesis

Indexed keywords

AMINOTRANSFERASE; GLYCYRRHIZIC ACID; INTERFERON; RIBAVIRIN;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CHRONIC HEPATITIS; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; COVARIANCE; FEMALE; HAZARD ASSESSMENT; HEPATITIS C; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SAMPLE SIZE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; GLYCYRRHIZIC ACID; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INJECTIONS, INTRAVENOUS; INTERFERON ALFA-2B; LIVER FUNCTION TESTS; LIVER NEOPLASMS; LONG-TERM CARE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33645894965     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-3177-0     Document Type: Article

References (27)

1. Bruix J, Calvet X, Costa J, et al.: Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 2:1004-1006, 1989
2. Colombo M, Kuo G, Choo QL, et al.: Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 2:1006-1008, 1989
3. Hasan F, Jeffers LJ, Medina MD, et al.: Hepatitis C-associated hepatocellular carcinoma. Hepatology 12:589-591, 1990
4. Kew MC, Houghton M, Choo QL, et al.: Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma. Lancet 335:873-874, 1990
5. Ikeda K, Saitoh S, Koida I, et al.: A multivariate analysis of risk factors for hepatocellular carcinogenesis - a prospective observation of 795 cases with viral and alcoholic cirrhosis. Hepatology 18:47-53, 1993
6. Kasahara A, Hayashi N, Mochizuki K. et al.: Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 27:1394-1402, 1998
7. Ikeda K, Saitoh S, Arase Y, et al.: Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C - a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 29:1124-1130, 1999
8. Yabu K, Kiyosawa K, Mori H, et al.: Serum collagen type IV for the assessment of fibrosis and resistance to interferon therapy in chronic hepatitis C. Scand J Gastroenterol 29:474-479, 1994
9. Nishiguchi S, Kuroki T, Nakatani S, et al.: Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346:1051-1055, 1995
10. Mazzella G, Accogli E, Sottili S, et al.: Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 24:141-147, 1996
11. Benvegnu L, Chemello L, Noventa F, et al.: A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 83:901-909, 1998
12. Oka H, Yamamoto S, Kuroki T, et al.: Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 76:743-749, 1995
13. Tarao K, Rino Y, Ohkawa S, et al.: Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer 86:589-595, 1999
14. Fujisawa K, Watanabe Y, Kimura K: Therapeutic approach to chronic active hepatitis with glycyrrhizin. Asian Med J 23:745-756, 1980
15. Suzuki H, Ohta Y, Takino T, et al.: Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis. Double blind trial. Asian Med J 26:423-438, 1983
16. Wildhirt E: Experience in Germany with glycyrrhizinic acid for the treatment of chronic viral hepatitis. In: Viral Hepatitis and Liver Disease 658-661, 1994, Springer Verlag, Germany
17. Rossum TGJ van, Vulto AG, Hop WCJ, et al.: Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J Gastroenterol Hepatol 14:1093-1099, 1999
18. Arase Y, Ikeda K, Murashima N, et al.: The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 79:1494-1500, 1997
19. Desmet VJ, Gerber M, Hoofnagle JH, et al.: Classification of chronic hepatitis: diagnosis, grading, and staging. Hepatology 19:1513-1520, 1994
20. Kaplan EL, Meier P: Nonparametric estimation for incomplete observation. J Am Stat Assoc 53:457-481, 1958
21. Cox DR: Regression models and life tables. J R Stat Soc 34:248-275, 1972
22. SPSS Inc. SPSS for Windows version 11.0 manual. Chicago, SPSS Inc., 2001
23. Nevens F, Goubau P, Van Eyken P, et al.: Treatment of decompensated viral hepatitis B-induced cirrhosis with low doses of interferon alpha. Liver 13:15-19, 1993
24. Tarao K, Takemiya S, Tamai S, et al.: Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer, 79:688-694, 1997
25. Gaeta GB, Rapicetta M, Sardaro C, et al.: High prevalence of co-occurrence of anti-HCV and anti-HBc antibodies in chronic hepatitis patients from southern Italy. Ital J Gastroenterol 22:350-351, 1990
26. Yu MC, Yuan JM, Ross RK, et al.: Presence of antibodies to hepatitis B surface antigen is associated with an excess risk for hepatocellular carcinoma among non-Asians in Los Angeles county, California. Hepatology 25:226-228, 1997
27. Koike K, Kobayashi M, Gondo M, et al.: Hepatitis B virus DNA is frequently found in liver biopsy samples from hepatitis C virus-infected chronic hepatitis patients. J Med Virol 54:249-255, 1998